Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September

Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027

Session Reserved for Dr Simon Walsh, Chief Scientific Officer, Queright

By | 16 April 2026

An Update into the Application of Imaging-Based Machine Learning in Fibrotic Lung Disease

Session Reserved for Dr Simon Walsh, Chief Scientific Officer, Queright

Session Reserved for Dr Simon Walsh, Chief Scientific Officer, Queright

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By